Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).

In late December 2019, the first pneumonia cases of unknown origin were identified in Wuhan, the capital city of Hubei province in central China.¹ The causative pathogen has been identified as a novel enveloped RNA betacoronavirus.² Given the phylogenetic similarity to the previously isolated severe acute respiratory syndrome coronavirus (SARS-CoV), the new virus has been named SARS-CoV-2.³

We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung.

In spite of the massive efforts in researching and developing mobile ad hoc networks in the last decade, this type of network has not yet witnessed mass market deployment. The low commercial penetration of products based on ad hoc networking technology could be explained by noting that the ongoing research is mainly focused on implementing military or specialized civilian applications. On the other hand, users are interested in general-purpose applications where high bandwidth and open access to the Internet are consolidated and cheap commodities. To turn mobile ad hoc networks into a commodity, we should move to more pragmatic "opportunistic ad hoc networking" in which multihop ad hoc networks are not isolated self-configured networks, but rather emerge as a flexible and low-cost extension of wired infrastructure networks coexisting with them. Indeed, a new class of networks is emerging from this view: mesh networks. This article provides an overview of mesh networking technology. In particular, starting from commercial case studies we describe the core building blocks and distinct features on which wireless mesh networks should be based. We provide a survey of the current state of the art in off-the-shelf and proprietary solutions to build wireless mesh networks. Finally, we address the challenges of designing a high-performance, scalable, and cost-effective wireless mesh network.

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.